The functional performance of the Argus II retinal prosthesis

Area of Science:

• Biomedical Engineering
• Neuroscience
• Ophthalmology

Background:

• Profound vision loss impacts millions globally.
• Current treatments for blindness are limited.
• Visual prostheses offer a potential solution by stimulating the visual pathway.

Purpose of the Study:

• To review the performance of the Argus II retinal implant.
• To discuss the development and future potential of visual prostheses.
• To evaluate the Argus II's role in restoring sight.

Main Methods:

• The Argus II retinal implant features 60 electrodes for electrical stimulation.
• The device targets surviving retinal neurons in patients with vision loss.
• This review analyzes data from ongoing safety/benefit studies.

Main Results:

• The Argus II is the first commercially available visual prosthesis.
• It received European conformity in 2011 and FDA approval in 2013 for humanitarian use.
• Ongoing studies continue to assess its long-term safety and efficacy.

Conclusions:

• The Argus II represents a significant advancement in restoring vision.
• Further research and development are expected to improve visual prosthesis technology.
• The device shows promise in addressing profound vision loss.